HR and breast cancer: Nodal involvement in clinical and pathological examination is one of the best known negative prognostic factors for all BC subtypes, including HR+/HER2− eBC, as reported by several randomized clinical trials and meta-analyses [16,17,18,20,39,40,41,42,43,44].